Related Experiment Video
Updated: Jun 13, 2026

A Model to Simulate Clinically Relevant Hypoxia in Humans
Published on: December 22, 2016
Sleep apnea and cardiovascular disease
Alexander G Logan1, T Douglas Bradley
1Mount Sinai Hospital, 435-600 University Avenue, Toronto, ON, M5G 1X5, Canada. logan@lunenfeld.ca
Insights
Cardiovascular disease remains a leading cause of death. While sleep apnea is common in these patients, its long-term benefits and ideal treatments require further study through randomized controlled trials.
Area of Science:
- Cardiology
- Sleep Medicine
- Public Health
Background:
- Cardiovascular disease (CVD) is the primary cause of mortality in North America.
- Sleep apnea affects roughly 50% of CVD patients, elevating their cardiovascular risk.
- Current treatments like continuous positive airway pressure (CPAP) show short-term benefits, but long-term advantages are unclear.
Purpose of the Study:
- To evaluate the necessity of identifying new treatable conditions for improving cardiovascular disease outcomes.
- To assess the role of sleep apnea in cardiovascular disease and the efficacy of its treatments.
Main Methods:
- Review of current understanding of sleep apnea in cardiovascular disease.
- Discussion of existing treatments (CPAP) and emerging alternatives (adaptive servo-ventilation).
- Emphasis on the need for randomized controlled trials (RCTs) to establish long-term benefits.
Main Results:
- The long-term benefits of continuous positive airway pressure for cardiovascular disease remain elusive.
- Alternative treatments for central sleep apnea are under investigation.
- Evidence is insufficient to recommend routine sleep apnea screening or treatment for asymptomatic cardiovascular disease patients.
Conclusions:
- Randomized controlled trials are essential to determine if treating sleep apnea improves survival and reduces cardiovascular disease risk.
- Current evidence does not support routine screening for sleep apnea in cardiovascular disease risk assessment.
- Treatment of sleep apnea is not currently recommended for preventing or managing cardiovascular disease in asymptomatic individuals.
Abstract:
Cardiovascular disease is still the leading cause of death in North America. To improve outcomes, it will likely be necessary to identify new potentially treatable conditions. Sleep apnea affects approximately 50% of patients with cardiovascular disease and is associated with increased cardiovascular risk. Continuous positive airway pressure is currently the treatment of choice and has many short-term favorable effects. The long-term benefits, however, remain elusive. Further, it may not be the ideal treatment for central sleep apnea, and the benefits of alternatives such adaptive servo-ventilation are currently being tested. Randomized controlled trials are now needed to determine whether treating sleep apnea will improve survival and reduce cardiovascular disease risk. Until better evidence becomes available, testing for sleep apnea cannot be recommended as part of the routine cardiovascular disease risk assessment, nor can its treatment be recommended for the prevention or management of cardiovascular disease in asymptomatic patients.
Related Concept Videos
Sleep Apnea
The condition is more prevalent among...
Other Pulmonary Disorders
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Coronary Artery Disease I: Introduction
Coronary Artery Disease III: Clinical Manifestations
Cardiovascular Drugs: Classification based on Therapeutic Indications
